Modeling the Aqueous-Phase Copper Ion-Exchange Behavior onto SSZ-13 Zeolites

Copper-exchanged zeolites are utilized as catalysts for the selective catalytic reduction of nitrogen oxides, which are atmospheric pollutants found in diesel engine exhaust. The total amount of copper ions and the types of copper species (Cu(II) or Cu(II)OH) exchanged onto a zeolite can be varied. Copper is exchanged onto SSZ-13 (an aluminosilicate zeolite with the chabazite topology) during a process known as aqueous ion exchange, where the zeolite is mixed in a copper-containing solution. The distribution of copper on SSZ-13 is influenced by exchange conditions, including the molarity, temperature, and pH of the copper solution. The effect of exchange conditions on the amount and type of copper exchanged onto SSZ-13 has not been thoroughly investigated. In order to study these effects, ion exchange experiments were performed with solutions containing different copper concentrations and pHs. The copper loading (wt%) of each SSZ-13 sample was determined by atomic absorption spectroscopy (AAS). Data from AAS shows that SSZ-13 samples exchanged in solutions with higher copper molarities have higher copper loadings. Further exchanges are being done to test the effects of pH on the amount and type of copper species exchanged onto SSZ-13 through characterization by AAS and temperature programmed desorption (TPD). Using the collected data, a model will be developed to predict the amount and distribution of copper on SSZ-13 based on the exchange conditions

Selinexor in advanced, metastatic dedifferentiated liposarcoma: A multinational, randomized, double-blind, placebo-controlled trial

PURPOSE: Antitumor activity in preclinical models and a phase I study of patients with dedifferentiated liposarcoma (DD-LPS) was observed with selinexor. We evaluated the clinical benefit of selinexor in patients with previously treated DD-LPS whose sarcoma progressed on approved agents. METHODS: SEAL was a phase II-III, multicenter, randomized, double-blind, placebo-controlled study. Patients age 12 years or older with advanced DD-LPS who had received two-five lines of therapy were randomly assigned (2:1) to selinexor (60 mg) or placebo twice weekly in 6-week cycles (crossover permitted). The primary end point was progression-free survival (PFS). Patients who received at least one dose of study treatment were included for safety analysis (ClinicalTrials.gov identifier: NCT02606461). RESULTS: Two hundred eighty-five patients were enrolled (selinexor, n = 188; placebo, n = 97). PFS was significantly longer with selinexor versus placebo: hazard ratio (HR) 0.70 (95% CI, 0.52 to 0.95; one-sided CONCLUSION: Patients with advanced, refractory DD-LPS showed improved PFS and time to next treatment with selinexor compared with placebo. Supportive care and dose reductions mitigated side effects of selinexor. Prospective validation o

Real-world outcomes of patients with locally advanced or metastatic epithelioid sarcoma

BACKGROUND: Limited data are available on the real-world effectiveness and safety of systemic therapies for advanced (surgically unresectable and/or metastatic) epithelioid sarcoma (ES). METHODS: A retrospective medical records review was conducted in patients with advanced ES who were initiating first-line or ≥2 lines of systemic therapy (2000-2017) at 5 US cancer centers. The real-world overall response rate (rwORR), the duration of response (rwDOR), the disease control rate (rwDCR) (defined as stable disease for ≥32 weeks or any duration of response), and progression-free survival (rwPFS) were assessed by radiology reports. Overall survival (OS), rwDOR, and rwPFS were estimated from the time therapy was initiated using the Kaplan-Meier method. Serious adverse events were assessed. RESULTS: Of 74 patients (median age at diagnosis, 33 years; range, 10.6-76.3 years), 72% were male, and 85% had metastatic disease. The median number of lines of therapy was 2 (range, 1-7 lines of therapy), and 46 patients (62%) received ≥2 lines of systemic therapy. First-line regimens were usually anthracycline-based (54%) or gemcitabine-based (24%). For patients receiving first-line systemic therapy, the rwORR was 15%, the rwDCR was 20%, the median rwDOR was 3.3 months (95% CI, 2.1-5.2 months), the median rwPFS was 2.5 months (95% CI, 1.7, 6.9 months), and the median OS was 15.2 months (95% CI, 11.4-21.7 months). For those who received ≥2 lines of systemic therapy, the rwORR was 9%, the rwDCR was 20%, the median rwDOR was 4.5 months (95% CI, 0.7-5.6 months), and the median rwPFS was 6.0 months (95% CI, 3.2-7.4 months). Over one-half of patients (51.4%) experienced an adverse event, most frequently febrile neutropenia (14%), pain (10%), anemia, dyspnea, fever, thrombocytopenia, or transaminitis (5% each). CONCLUSIONS: Systemic therapies demonstrate limited efficacy in patients with advanced ES and have associated toxicities

Therapeutic efficacy of favipiravir against Bourbon virus in mice

Bourbon virus (BRBV) is an emerging tick-borne RNA virus in the orthomyxoviridae family that was discovered in 2014. Although fatal human cases of BRBV have been described, little is known about its pathogenesis, and no antiviral therapies or vaccines exist. We obtained serum from a fatal case in 2017 and successfully recovered the second human infectious isolate of BRBV. Next-generation sequencing of the St. Louis isolate of BRBV (BRBV-STL) showed >99% nucleotide identity to the original reference isolate. Using BRBV-STL, we developed a small animal model to study BRBV-STL tropism in vivo and evaluated the prophylactic and therapeutic efficacy of the experimental antiviral drug favipiravir against BRBV-induced disease. Infection of Ifnar1-/- mice lacking the type I interferon receptor, but not congenic wild-type animals, resulted in uniformly fatal disease 6 to 10 days after infection. RNA in situ hybridization and viral yield assays demonstrated a broad tropism of BRBV-STL with highest levels detected in liver and spleen. In vitro replication and polymerase activity of BRBV-STL were inhibited by favipiravir. Moreover, administration of favipiravir as a prophylaxis or as post-exposure therapy three days after infection prevented BRBV-STL-induced mortality in immunocompromised Ifnar1-/- mice. These results suggest that favipiravir may be a candidate treatment for humans who become infected with BRBV

Operator Product Expansion for Exclusive Decays: B^+ ->Ds^+ e+e- and B^+ -> Ds^{*+} e+e-

The decays $B^+\to D_{s,d}^+e^+e^-$ and $B^+\to D_{s,d}^{*+}e^+e^-$ proceed through a weak and an electromagnetic interaction. This is a typical ``long distance'' process, usually difficult to compute systematically. We propose that over a large fraction of phase space a combination of an operator product and heavy quark expansions effectively turns this process into one in which the weak and electromagnetic interactions occur through a local operator. Moreover, we use heavy quark spin symmetry to relate all the local operators that appear in leading order of the operator expansion to two basic ones. We use this operator expansion to estimate the decay rates for $B^+\to D_{s,d}^{(*)+}e^+e^-$.Comment: 4 pages, 1 figure, Latex, published version in PR